Dr. Wrangle Discusses Phase 2b QUILT 3.055 Trial at IASLC 2024 World Conference on Lung Cancer

John Wrangle, MD, MPH, of the Medical University of South Carolina, joined Lung Cancers Today at the IASLC 2024 World Conference on Lung Cancer to discuss data he presented on the phase 2b QUILT 3.055 trial during the oral abstract session titled “Novel Immunotherapy Strategies and Combinations.”

The trial is investigating the IL-15 superagonist nogapendekin alfa inbakicept-pmln, also known as N-803, in combination with a checkpoint inhibitor in patients with non-small cell lung cancer (NSCLC) who stopped responding to checkpoint inhibitor therapy.

“The significance of this study has been to look at a population of patients who have responded or had stable disease as their best prior response, and at the time of their progression on checkpoint inhibition, to add N-803 to attempt to resuscitate benefit from immunotherapy,” Dr. Wrangle said.

Dr. Wrangle shared what the trial showed about adding N-803 to checkpoint inhibitors in patients with NSCLC who progressed on checkpoint inhibitor therapy, explaining that the median overall survival for all patients in the trial was 14.1 months, with 57% of patients alive at one year.

“Importantly, patients who had stable disease as their best prior response to prior checkpoint inhibition were able to get into partial responses… indicating that with the addition of N-803, prior stable disease with immunotherapy was able to be converted to responsive disease,” he said.

According to Dr. Wrangle, the data shows a “promising clinical signal plus an encouraging median overall survival,” and highlighted additional trials of the IL-15 superagonist. These trials include the phase 3 ResQ301 and ResQ302 trials, comparing nogapendekin alfa inbakicept-pmln plus pembrolizumab or nivolumab in first- and second-line NSCLC.

Dr. Wrangle reflected on the progress made over the last decade regarding this therapy and approach.

“It’s a concept that I’ve been working on for 9 years now. Originally, the preclinical rationale developed in my laboratory with Mark Rubenstein and an investigator-initiated trial,” Dr. Wrangle said. “It’s really gratifying to be able to present further updated results in 86 patients with non-small cell lung cancer and really looking forward to the performance of these ongoing industry trials in terms of developing a therapy from the laboratory into the clinic.”